Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a 6 mg per 0.5 mL solution for subcutaneous injection use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients who require rapid relief of headache and associated symptoms.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of healthcare providers across multiple regions.

Imigran (sumatriptan) belongs to the Triptan class and is used for the acute management of migraine.

- Migraine with aura: provides rapid relief of headache and associated neurological symptoms. - Migraine without aura: reduces pain intensity and duration when administered early in an attack. - Acute episodic migraine: aborts an attack and improves functional ability during the episode.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Tingling or numbness: transient paresthesia in the face or extremities. - Warmth or flushing: sensation of heat or redness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate coronary vasospasm. - Severe hypertension: sudden increase in blood pressure. - Allergic reaction: rash, swelling, or anaphylaxis.

Before using Imigran, consider the following precautions. - Cardiovascular assessment: review history of ischemic heart disease, angina, or uncontrolled hypertension before prescribing. - Concomitant serotonergic drugs: avoid use with other triptans or MAO inhibitors due to serotonin syndrome risk. - Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. - Age considerations: safety not established in pediatric patients; reserve for adults. - Renal or hepatic impairment: adjust use cautiously in severe dysfunction. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Sumatriptan may interact with several medication classes.

Major Interactions (Avoid): - Other triptans: additive vasoconstriction risk. - Ergot alkaloids: increased vasospasm potential. - Monoamine oxidase inhibitors (MAOIs): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: monitor for signs of serotonin syndrome. - Antihypertensive agents: may enhance blood‑pressure‑lowering effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma concentrations.